Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell(Instituto Oncológico Dr. Rosell), Miquel Tarón(Universitat Autònoma de Barcelona), Guillermo López-Vivanco(Hospital de Cruces), Ramón Palmero(Institut Català d'Oncologia), J.L. González-Larriba(Hospital Clínico San Carlos), Rosario García‐Campelo, Clara Mayo(USP Institut Universitari Dexeus), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Carlos Camps(Universitat de València), Cristina Queralt(Universitat Autònoma de Barcelona), Miguel Ángel Molina‐Vila(Hospital Universitario Dexeus), Roman Bastus(University Hospital Mútua de Terrassa), Margarita Majem(Chinese Academy of Medical Sciences & Peking Union Medical College), Isabel Bover(Hospital Universitari Sant Joan de Reus), Miguel Ángel Moreno(Complejo Hospitalario de Jaén), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Dolores Isla(Hospital Clínico Universitario Lozano Blesa), Mariano Provencio(Hospital Universitario Puerta de Hierro Majadahonda), Noemı́ Reguart(Hospital Clínic de Barcelona), José Miguel Sánchez(Research Institute Hospital 12 de Octubre), Rut Porta(Catalan Institute for Water Research), Sílvia Catot(Althaia), José Javier Sánchez(Research Institute Hospital 12 de Octubre), Teresa Morán(Institute of Agrifood Research and Technology), Bartomeu Massutí(Universitat de Miguel Hernández d'Elx), Jordi Bertran-Alamillo(USP Institut Universitari Dexeus), Amelia Insa(Hospital Clínico Universitario de Valencia)
Cited by 2,375
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k